Plasmablastic lymphoma in Malawi by Chiyoyola, Sarah et al.
SHORT REPORT Open Access
Plasmablastic lymphoma in Malawi
Takondwa Zuze1, Matthew S. Painschab1,2, Ryan Seguin1,2, Evarista Kudowa1, Bongani Kaimila1,
Edwards Kasonkanji1, Tamiwe Tomoka1,3, Bal Mukunda Dhungel1,2, Maurice Mulenga4, Maria Chikasema1,
Blessings Tewete1, Asekanadziwa Ntangwanika1, Sarah Chiyoyola1, Fred Chimzimu1, Coxcilly Kampani1,
Robert Krysiak1,2, Nathan D. Montgomery2, Yuri Fedoriw2 and Satish Gopal1,2,3*
Abstract
Plasmablastic lymphoma (PBL) clinical descriptions are scarce from sub-Saharan Africa (SSA) where both HIV and
EBV are highly endemic. We identified 12 patients with pathologically confirmed PBL from a prospective cohort in
Lilongwe, Malawi. Median age was 46 (range 26–71), seven (58%) were male, and six (50%) were HIV-positive. Eight
patients were treated with CHOP and four with a modified EPOCH regimen. One-year overall survival was
56% (95% CI 24–79%), without clear differences based on HIV status. PBL occurs in Malawi in HIV-positive and HIV-
negative individuals and can be treated successfully with curative intent, even in a low-resource setting in SSA.
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Introduction
Plasmablastic lymphoma (PBL) is an aggressive
non-Hodgkin lymphoma (NHL) subtype associated with
human immunodeficiency virus (HIV) infection [1], con-
stituting 2% of all HIV-associated lymphomas [2]. Des-
pite strong association with HIV, PBL is also seen in
HIV-negative patients [3, 4]. Epstein-Barr virus (EBV)
increases plasmablasts in blood and lymph nodes in the
presence or absence of HIV, and may play a direct role
in PBL development [5].
Despite high prevalence of HIV infection in
sub-Saharan Africa (SSA), PBL descriptions from the re-
gion are scarce. We describe characteristics, treatment,
and outcomes of PBL patients enrolled in a prospective,
observational cohort in Malawi. This is among the first
detailed clinical descriptions of this unique and aggres-
sive NHL subtype from SSA, where HIV and EBV are
endemic.
Methods
We identified patients with PBL enrolled in the prospect-
ive Kamuzu Central Hospital Lymphoma Study between
May 2013 and May 2017 in Lilongwe, Malawi. PBL diag-
noses were histologically and immunophenotypically
confirmed, and underwent subsequent secondary review
in the United States [6]. All cases were positive for CD138
and negative for CD20 with Ki67 > 90%.
Following diagnosis, all patients underwent standardized
clinical, laboratory, and radiologic assessments as previ-
ously described [7]. Before August 2016, patients were
treated with CHOP (cyclophosphamide 750 mg/m2, doxo-
rubicin 50 mg/m2, vincristine 1.4 mg/m2 day 1, and pred-
nisone 40 mg/m2 days 1–5; 21 day cycles). After August
2016, patients received a modified EPOCH regimen (eto-
poside 50 mg/m2, vincristine 0.4 mg/m2, and doxorubicin
10 mg/m2 days 1–4, prednisone 60 mg/m2 days 1–5, and
cyclophosphamide 750 mg/m2 day 1; 21-day cycles). Be-
cause the local clinical environment does not allow safe
administration of 24-h continuous infusions, 24-h doses
of etoposide, vincristine, and doxorubicin were instead ad-
ministered over 6–8 h on successive days. Hematopoietic
growth factors were not available. All HIV-infected pa-
tients received antiretroviral therapy (ART) concurrent
with chemotherapy.
Cohort characteristics were summarized using simple
descriptive statistics. Patients were followed until death
or administrative censoring on September 30, 2017. Ad-
verse events were reported using National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
version 4.0. Kaplan-Meier methods were used to esti-
mate overall survival (OS). Analyses were conducted
using Stata version 14.1 (College Station, Texas).
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Results
Of 183 adults with pathologically confirmed NHL
during the study period, we identified 12 patients
with PBL (Table 1). Median age was 46 years (range
26–71), seven (58%) were male, and six (50%) were
HIV-positive. Of HIV-positive patients, three were di-
agnosed with HIV prior to PBL diagnosis, and had
been on ART for 6, 10, and 14 months. Among
HIV-positive patients, median CD4 cell count was
147 cell/μL (range 9–460) and three (50%) had sup-
pressed HIV RNA < 400 copies/mL at PBL diagnosis.
Of seven patients whose tumors were tested for
EBV-encoded RNA (EBER) by in situ hybridization,
five (71%) were positive: 3/3 HIV-positive, 2/4
HIV-negative. All patients had a primary site of dis-
ease in the head and neck. Nine (75%) patients had
Ann Arbor stage I/II disease. Median lactate dehydro-
genase was 339 IU/L (range 186–2522 IU/L, upper
limit of normal 250 IU/L).
Eight patients were treated with CHOP for a median
of six cycles (range 1–8). Four patients received the
modified EPOCH regimen for a median of five cycles
(range 2–6). All patients receiving EPOCH and 50% of
CHOP recipients experienced treatment delay due to
grade 3/4 neutropenia and one CHOP recipient experi-
enced delay due to grade 3 anemia. Overall, five (42%)
patients achieved a complete response (CR) after chemo-
therapy [CHOP 2/8 (25%); EPOCH 3/4 (75%)]. Both pa-
tients who achieved CR after CHOP relapsed 4 months
after treatment completion.
As of September 30, 2017, vital status was known for
all patients and median follow-up was 13 months (range
1–35) among patients still alive. One-year OS was 56%
(95% CI 24–79%, Fig. 1). No differences were observed
between HIV-positive patients (1-year OS 67, 95% CI
19–90%) and HIV-negative patients (1-year OS 42, 95%
CI 6–77%, p = 0.53). Of seven deaths, one was due to
neutropenic sepsis and six due to lymphoma
progression.
Discussion
In resource-rich settings, PBL is a rare lymphoma subtype
with poor outcomes [8, 9]. The current National Compre-
hensive Cancer Network guidelines recommend intensive
chemotherapy regimens such as dose-adjusted EPOCH,
hyper-CVAD (cyclophosphamide, vincristine, doxorubicin,
dexamethasone alternating with cytarabine, methotrex-
ate), or CODOX-M/IVAC (cyclophosphamide, vincristine,
doxorubicin, methotrexate alternating with ifosfamide,
etoposide, cytarabine). Consolidative high-dose chemo-
therapy and autologous stem cell rescue in first remission
is also recommended by some [10]. Ongoing studies in
high-income countries are attempting to investigate
anti-myeloma agents (bortezomib, daratumumab, etc.)
added to aggressive NHL chemotherapy regimens to im-
prove outcomes, based on plasmacytic differentiation of
PBL tumor cells [11, 12]. Conversely, other studies have
demonstrated similar or worse results after intensive
chemotherapy regimens compared with CHOP due to ex-
cess treatment-related complications [10, 13].
Table 1 Baseline characteristics of plasmablastic lymphoma patients from the Kamuzu Central Hospital Lymphoma Cohort study
Total (n = 12) HIV+ (n = 6) HIV- (n = 6)
Age, years, median (range) 46 (26–71) 39 (30–60) 53 (26–71)
Male sex, n (%) 7 (58) 2 (33) 5 (83)
Largest tumor location head and neck, n (%) 12 (100) 6 (100) 6 (100)
CNS involvement, n (%) 1 (8) 0 (0) 1 (17)
Bone marrow involvement, n (%) 3 (25) 2 (33) 1 (17)
Largest diameter of mass, cm, median (range) 10 (3–22) 8 (3–15) 11 (10–22)
Ann Arbor stage I/II, n (%) 9 (75) 6 (100) 3 (50)
Performance score≥ 2, n (%) 1 (8) 0 (0) 1 (17)
White blood cells, 103/uL, median (range) 4.6 (2.7–14.9) 11.6 (6.2–12.5) 6.1 (2.7–14.9)
Absolute neutrophils, 103/uL, median (range) 2.74 (0.92–10.6) 2.55 (0.9–4.07) 2.48 (1.3–10.6)
Hemoglobin, g/dL, median (range) 11 (6.2–14.9) 11.6 (6.2–12.5) 10.9 (10.1–14.9)
Platelets, 103/uL, median (range) 206 (103–666) 210 (176–666) 233 (103–458)
Lactate dehydrogenase (LDH), IU/L, median (range)a 338 (186–2522) 328 (240–2522) 226 (186–1803)
CD4 count, cells/μL, median (range) ― 147 (9–460) ―
HIV RNA < 400 copies/mL, n (%) ― 3 (50) ―
EBER expression n (%) 5 (71) 3 (100) 2 (50)
Abbreviations: CNS Central nervous system, EBV Epstein Barr virus, EBER EBV encoded RNA, ECOG PS Eastern oncology cooperative group performance status, HIV
human immunodeficiency virus, LDH lactate dehydrogenase
aLDH normal range = 0–250 IU/L
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Upon first recognition of PBL in Malawi, and due to
supportive care constraints, we initially treated partici-
pants with CHOP resulting in a 25% CR rate, with nearly
all patients dying of progressive disease rather than
treatment-related complications. Given these poor out-
comes, we intensified our approach to a modified
EPOCH regimen adapted as required by clinic infra-
structure, resulting in a 75% CR rate, although follow-up
time for this more recently treated group is limited.
Nevertheless, this experience illustrates that even in a
resource-limited country, sustained investments in cancer
diagnostic and treatment capabilities can lead to recogni-
tion of new tumor types, foundational understanding of
outcomes using standard approaches, and evidence-based
adjustment of therapeutic approaches.
HIV-positive and HIV-negative patients with PBL have
different clinical and pathologic characteristics, including
better response to chemotherapy in HIV-positive patients
[14]. HIV-positive PBL patients are younger, predominantly
male, and have more frequent oral involvement.
HIV-positive PBL cases have significantly higher expression
of CD20, CD56, and EBER compared with HIV-negative
PBL. HIV-positive patients with PBL have also been re-
ported to have better survival than HIV-negative patients
with PBL [14]. We found no difference in OS between
HIV-positive and HIV-negative patients, although our sam-
ple size is small and trends in OS by HIV status were simi-
lar to those described in high-income countries.
Previous studies have indicated that PBL is closely as-
sociated with EBV infection. A metanalysis of PBL cases
demonstrated EBV by in situ hybridization in 75% of
HIV-infected cases and 50% of HIV-uninfected cases [9].
Similarly, our findings confirmed EBV presence in 3/3
HIV-positive cases but only 2/4 HIV-negative cases.
Strengths of our study include its prospective longitu-
dinal nature, no loss to follow-up, standardized treatment,
and pathologic confirmation using immunohistochemistry
and telepathology consultation, all of which are not com-
mon in studies of lymphoproliferative disorders in SSA.
Limitations are small sample size and relatively short
follow-up. Ongoing enrollment and long-term follow-up
will allow better understanding of prognostic factors and
outcomes.
In conclusion, PBL occurs in SSA and may be under-
diagnosed in many settings. Further study is needed to
identify best treatment approaches, but our early experi-
ence suggests treatment intensification might lead to
better outcomes for this population even in highly
resource-limited environments.
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Fig. 1 Overall survival of plasmablastic lymphoma patients in Lilongwe stratified by HIV status. No difference was found between HIV+ and HIV-
patients by log-rank test
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